Company Analysis - Genentech
Walking with Giants
Genentech has come a long way in its 30 year history.
From being arguably the first true biotech drug company, it has grown to become a Top 30 pharmaceutical concern in terms of its pipeline size. Although nominally owned by Swiss-giant Hoffmann-La Roche, it continues to operate with an enviable degree of independence, although paradoxically it is its shrewd choice of partners which truly marks it out.
The success of Genentech as a biotechnology company is indeed in no small part derived from its strategy of forming alliances with smaller companies, whose proprietary drugs and technology platforms have the potential to become blockbusters. Historically, this approach has brought Genentech great rewards, particularly in the field of oncology, and now the company is hoping to achieve similar success in new therapeutic areas.
